Alnylam Pharmaceuticals Inc (ALNY)vsRoyalty Pharma Plc (RPRX)
ALNY
Alnylam Pharmaceuticals Inc
$312.17
+0.34%
HEALTHCARE · Cap: $42.29B
RPRX
Royalty Pharma Plc
$45.36
-0.37%
HEALTHCARE · Cap: $26.53B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 56% more annual revenue ($3.71B vs $2.38B). RPRX leads profitability with a 32.4% profit margin vs 8.4%. RPRX trades at a lower P/E of 25.8x. RPRX earns a higher WallStSmart Score of 61/100 (C+).
ALNY
Hold49
out of 100
Grade: D+
RPRX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1934.6%
Fair Value
$15.84
Current Price
$312.17
$296.33 premium
Margin of Safety
-17.3%
Fair Value
$37.74
Current Price
$45.36
$7.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 57.7%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 52.4x book value
Moderate valuation
4.8% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin. Profitability is solid with margins at 32.4% and operating margin at 57.7%. PEG of 1.39 suggests the stock is reasonably priced for its growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 136.9x leaves little room for execution misses.
Bear Case : RPRX
The primary concerns for RPRX are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while RPRX is a value play — different risk/reward profiles.
RPRX carries more volatility with a beta of 0.42 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
RPRX generates stronger free cash flow (827M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (61/100 vs 49/100), backed by strong 32.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?